ICER’s ‘Unsupported Price Increase’ Report Due This Fall
Executive Summary
Report by the Institute for Clinical and Economic Review will seek to inform the public policy debate on price increases for prescription drugs.
You may also be interested in...
ICER Chief Scientific Officer Bradt Brings Pharma Perspective
Pamela Brandt joins health technology assessment group after stints at Aegerion, Astellas and Abbott Labs.
Missed Opportunities: 10 Questions We Wish Senators Had Asked At The Drug Pricing Hearing
Getting seven top pharma leaders in the same room, required to answer tough questions on drug pricing, is rare. Members of the Senate Finance Committee got that opportunity recently, but there are some questions our Pink Sheet reporters think they missed.
Arnold Foundation Will Retain Drug Pricing Focus As Health Care Agenda Grows
In an interview with the Pink Sheet, Laura and John Arnold Foundation VP Health Care Mark Miller discusses the foundation’s ongoing drug pricing priorities.